New treatment for advanced breast cancer.
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000077267:Fulvestrant; D006801:Humans; D009362:Neoplasm Metastasis; D014481:United States; D014486:United States Food and Drug Administration
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D000077267:Fulvestrant; D004958:Estradiol